troglitazone has been researched along with African Lymphoma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takenokuchi, M | 1 |
| Saigo, K | 1 |
| Nakamachi, Y | 1 |
| Kawano, S | 1 |
| Hashimoto, M | 1 |
| Fujioka, T | 1 |
| Koizumi, T | 1 |
| Tatsumi, E | 1 |
| Kumagai, S | 1 |
1 other study available for troglitazone and African Lymphoma
| Article | Year |
|---|---|
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Cell | 2006 |